Xeris Biopharma Holdings, Inc. XERS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 85.4%+3.6pp | 81.9%-0.7pp | 82.5%+3.1pp | 79.5%+6.3pp | |
| Operating margin | 8.5%+25.9pp | -17.4%+9.5pp | -26.8%+47.5pp | -74.3%+158pp | |
| Net margin | 0.2%+27.2pp | -27%+11.0pp | -38%+47.9pp | -85.9%+162pp | |
| Returns | |||||
| Return on invested capital | 15%+36.8pp | -21.7%+10.1pp | -31.9%+37.2pp | -69.1%+46.6pp | |
| Efficiency | |||||
| Asset turnover | 0.8×+0.2× | 0.6×+0.1× | 0.5×+0.2× | 0.3×+0.1× | |
| Liquidity | |||||
| Current ratio | 2.2×+0.5× | 1.7×0.0× | 1.6×-0.9× | 2.5×+0.7× | |
| Leverage | |||||
| Debt-to-equity | 18.9×— | —— | —— | 4.4×+3.5× | |
| Net debt / EBITDA | 5.6×— | —— | —— | —— | |
| Per Share | |||||
| Book value per share | $0.08+139% | -$0.20-309% | -$0.05-115% | $0.33-72.3% | |
| Valuation | |||||
| Market capitalization | $1.28B+76.9% | $505.39M+55.7% | $324.59M+79.5% | $180.86M-50.5% | |
| Price / earnings | 106.4×— | —— | —— | —— | |
| Price / sales | 4.1×+0.8× | 2.5×+0.5× | 2×+0.3× | 1.6×-5.7× | |
| Price / book | 98.2×— | —— | —— | 4×+0.2× | |
| EV / EBITDA | 38.3×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Xeris Biopharma Holdings, Inc.'s profit margins?
- Xeris Biopharma Holdings, Inc. (XERS) runs a 85.9% gross margin and a 11.4% operating margin, with a 3.8% net margin.
- Where do Xeris Biopharma Holdings, Inc.'s ratios come from?
- Every ratio is computed from Xeris Biopharma Holdings, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
